Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense, The American Journal of Human Genetics, vol.74, issue.1, pp.83-92, 2004. ,
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia, European Heart Journal, vol.32, issue.21, pp.2650-2659, 2011. ,
Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers, Current Opinion in Pharmacology, vol.5, issue.5, pp.550-555, 2005. ,
Structure and expression of the Huntington's disease gene: Evidence against simple inactivation due to an expanded CAG repeat, Somatic Cell and Molecular Genetics, vol.20, issue.1, pp.27-38, 1994. ,
Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss, Genes & Development, vol.30, issue.1, pp.34-51, 2016. ,
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function, Cell, vol.116, issue.04, pp.45-50, 2004. ,
MicroRNAs: Target recognition and regulatory functions, Cell, vol.136, issue.2, pp.215-233, 2009. ,
Bioconjugated oligonucleotides: Recent developments and therapeutic applications, Bioconjugate Chemistry, vol.30, pp.366-383, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02490446
Inotersen treatment for patients with hereditary transthyretin amyloidosis, New England Journal of Medicine, vol.379, issue.1, pp.22-31, 2018. ,
Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment, Molecular Therapy-Nucleic Acids, vol.1, 2012. ,
Mechanism of action of DNA topoisomerase inhibitors, Stem Cells, vol.13, issue.4, pp.369-379, 1995. ,
, Nusinersen. Australian Prescriber, vol.42, pp.75-76, 2019.
Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah?/?mdx mouse models of Duchenne muscular dystrophy, PLoS One, vol.13, issue.6, 2018. ,
Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 3 0 end of a transcript encoding a protein kinase family member, Cell, vol.68, issue.4, pp.799-808, 1992. ,
Duchenne muscular dystrophy: Patterns of clinical progression and effects of supportive therapy, Neurology, vol.39, issue.4, pp.475-481, 1989. ,
Gold therapy in rheumatoid arthritis, New England Journal of Medicine, vol.237, issue.12, pp.428-431, 1947. ,
The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy, Journal of Neurology, vol.240, issue.2, pp.105-112, 1993. ,
Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management, The Lancet Neurology, vol.9, issue.1, pp.70271-70277, 2010. ,
Oligodeoxynucleoside phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid, Journal of Biochemical and Biophysical Methods, vol.20, issue.3, pp.318-322, 1990. ,
Therapeutic miRNA and siRNA: Moving from bench to clinic as next generation medicine, Molecular Therapy. Nucleic Acids, vol.8, pp.132-143, 2017. ,
Improved survival with Vemurafenib in melanoma with BRAF V600E mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2516, 2011. ,
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): A phase 3, multicentre, open-label, randomised trial, The Lancet Oncology, vol.18, issue.4, pp.30168-30175, 2017. ,
Angelman syndrome: A review of the clinical and genetic aspects, Journal of Medical Genetics, vol.40, issue.2, pp.87-95, 2003. ,
NTRK fusion-positive cancers and TRK inhibitor therapy, Nature Reviews Clinical Oncology, vol.15, issue.12, pp.731-747, 2018. ,
Sequence variations in PCSK9, Low LDL, and protection against coronary heart disease, New England Journal of Medicine, vol.354, issue.12, pp.1264-1272, 2006. ,
Tabulation of human transthyretin (TTR) variants, vol.10, pp.160-184, 2003. ,
Lentiviral vectors can be used for full-length dystrophin gene therapy, Scientific Reports, vol.7, issue.1, p.79, 2017. ,
Integrated assessment of the clinical performance of GalNAc 3 -conjugated 2 0 -O-methoxyethyl chimeric antisense oligonucleotides: I. human volunteer experience, Nucleic Acid Therapeutics, vol.29, issue.1, pp.16-32, 2019. ,
Drugging the RNA world, Cold Spring Harbor Perspectives in Biology, vol.10, issue.11, 2018. ,
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides, Proceedings of the National Academy of Sciences, vol.90, issue.18, pp.8673-8677, 1993. ,
Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis, Journal of Cystic Fibrosis, vol.19, pp.99-107, 2019. ,
Trinucleotide repeat length instability and age of onset in Huntington's disease, Nature Genetics, vol.4, issue.4, pp.387-392, 1993. ,
PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules, Nature, vol.365, issue.6446, pp.566-568, 1993. ,
Population frequencies of inherited neuromuscular diseases-A world survey, Neuromuscular Disorders, vol.1, issue.1, pp.19-29, 1991. ,
T.I.2 exon skipping and PRO044 in Duchenne muscular dystrophy: Extending the program, Neuromuscular Disorders, vol.23, issue.9, p.847, 2013. ,
Nusinersen versus sham control in infantile-onset spinal muscular atrophy, New England Journal of Medicine, vol.377, issue.18, pp.1723-1732, 2017. ,
Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans, Nature, vol.391, issue.6669, pp.806-811, 1998. ,
A highly durable RNAi therapeutic inhibitor of PCSK9, New England Journal of Medicine, vol.376, issue.1, pp.41-51, 2017. ,
Mutational spectrum of DMD mutations in dystrophinopathy patients: Application of modern diagnostic techniques to a large cohort, Human Mutation, vol.30, issue.12, pp.1657-1666, 2009. ,
Nonsense-mediated mRNA decayin health and disease, Human Molecular Genetics, vol.8, issue.10, pp.1893-1900, 1999. ,
RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds, Nucleic Acids Research, vol.17, issue.22, pp.9193-9204, 1989. ,
Fomivirsen, Clinical Pharmacokinetics, vol.41, issue.4, pp.255-260, 2002. ,
A non-coding function of TYRP1 mRNA promotes melanoma growth, Nature Cell Biology, vol.19, pp.1348-1357, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01647130
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers, Nature Medicine, vol.21, issue.3, pp.270-275, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02407968
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo, PLoS One, vol.5, issue.5, 2010. ,
The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells, Cancer Research, vol.73, issue.3, pp.1180-1189, 2013. ,
Locked nucleic acid: Modality, diversity, and drug discovery, Drug Discovery Today, vol.23, issue.1, pp.101-114, 2018. ,
Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules, Nucleic Acids Research, vol.41, issue.13, pp.6687-6697, 2013. ,
Mipomersen sodium: First global approval, Drugs, vol.73, issue.5, pp.487-493, 2013. ,
No-go decay: A quality control mechanism for RNA in translation, Wiley Interdisciplinary Reviews: RNA, vol.1, pp.132-141, 2010. ,
Rearrangement of the human ABL oncogene in a glioblastoma, Cancer Research, vol.50, issue.11, pp.3429-3434, 1990. ,
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer, Science Translational Medicine, vol.7, issue.314, 2015. ,
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model, Genes & Development, vol.24, issue.15, pp.1634-1644, 2010. ,
Peripheral SMN restoration is essential for longterm rescue of a severe spinal muscular atrophy mouse model, Nature, vol.478, issue.7367, pp.123-126, 2011. ,
Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations, Genome Biology, vol.19, issue.1, 2018. ,
Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics, Molecular Therapy-Nucleic Acids, vol.6, pp.116-132, 2017. ,
The emerging role of lncRNAs in cancer, Nature Medicine, vol.21, issue.11, pp.1253-1261, 2015. ,
Synthesis and hybridization studies on two complementary nona (2 0 -o-methyl)ribonucleotides, Nucleic Acids Research, vol.15, issue.15, pp.6131-6148, 1987. ,
Treatment of HCV infection by targeting MicroRNA, New England Journal of Medicine, vol.368, issue.18, pp.1685-1694, 2013. ,
Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers, Cardiovascular Research, vol.85, issue.3, pp.444-453, 2010. ,
Tamoxifen: A most unlikely pioneering medicine, Nature Reviews Drug Discovery, vol.2, issue.3, pp.205-213, 2003. ,
Imatinib mesylate: Clinical results in Philadelphia chromosome-positive leukemias, Seminars in Oncology, vol.28, pp.9-18, 2001. ,
Gene therapy on the move, EMBO Molecular Medicine, vol.5, issue.11, pp.1642-1661, 2013. ,
Inotersen: First global approval, Drugs, vol.78, issue.13, pp.1371-1376, 2018. ,
The chemical evolution of oligonucleotide therapies of clinical utility, Nature Biotechnology, vol.35, issue.3, pp.238-248, 2017. ,
Patient-customized oligonucleotide therapy for a rare genetic disease, New England Journal of Medicine, vol.381, issue.17, pp.1644-1652, 2019. ,
Enhanced potency of GalNAc-conjugated antisense oligonucleotides in hepatocellular Cancer models, Molecular Therapy, vol.27, issue.9, pp.1547-1557, 2019. ,
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis, Neuron, vol.74, issue.6, pp.1031-1044, 2012. ,
The mononucleotidedependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5 0 -nucleotidase, Blood, vol.98, issue.4, pp.995-1002, 2001. ,
Silencing of microRNAs in vivo with 'antagomirs', Nature, vol.438, issue.7068, pp.685-689, 2005. ,
Antisense technologies. Improvement through novel chemical modifications, European Journal of Biochemistry, vol.270, issue.8, pp.1628-1644, 2003. ,
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection, Science, vol.327, issue.5962, pp.198-201, 2010. ,
Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts, Molecular Therapy: The Journal of the American Society of Gene Therapy, vol.7, issue.5, pp.68-74, 2003. ,
Executive and mnemonic functions in early Huntington's disease, Brain: A Journal of Neurology, vol.119, pp.1633-1645, 1996. ,
Epidemiology and natural history of hepatitis C virus infection, World Journal of Gastroenterology, vol.20, issue.28, pp.9270-9280, 2014. ,
Melanoma addiction to the long noncoding RNA SAMMSON, Nature, vol.531, issue.7595, pp.518-522, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02086933
Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: A meta-analysis, Future Oncology, vol.13, issue.12, pp.1115-1127, 2017. ,
mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway, Nucleic Acids Research, vol.47, issue.13, pp.6900-6916, 2019. ,
Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames, Nature Biotechnology, vol.34, issue.8, pp.875-880, 2016. ,
Antisense oligonucleotides targeting translation inhibitory elements in 5 0 UTRs can selectively increase protein levels, Nucleic Acids Research, vol.45, issue.16, pp.9528-9546, 2017. ,
Progression of transthyretin amyloid neuropathy after liver transplantation, Neurology, vol.75, issue.4, pp.324-327, 2010. ,
MicroRNAs and other non-coding RNAs as targets for anticancer drug development, Nature Reviews. Drug Discovery, vol.12, issue.11, pp.847-865, 2013. ,
Efficient suppression of hepatitis C virus replication by combination treatment with miR-122 antagonism and direct-acting antivirals in cell culture systems, Scientific Reports, vol.6, issue.1, p.30939, 2016. ,
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products, Science, vol.247, issue.4946, pp.1079-1082, 1990. ,
Angelman syndrome: Insights into genomic imprinting and neurodevelopmental phenotypes, Trends in Neurosciences, vol.34, issue.6, pp.293-303, 2011. ,
Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics, Gene Regulation and Systems Biology, vol.2, pp.275-295, 2008. ,
Targeted therapies: How personal should we go?, Nature Reviews Clinical Oncology, vol.9, issue.2, pp.87-97, 2012. ,
A day in the life of the spliceosome, Nature Reviews Molecular Cell Biology, vol.15, issue.2, pp.108-121, 2014. ,
Treating type 1 diabetes: From strategies for insulin delivery to dual hormonal control, Minerva Endocrinologica, vol.38, issue.2, pp.145-163, 2013. ,
Revealing the world of RNA interference, Nature, issue.7006, pp.338-342, 2004. ,
Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy, Annals of Neurology, vol.79, issue.2, pp.257-271, 2016. ,
Towards a therapy for Angelman syndrome by targeting a long non-coding RNA, Nature, vol.518, issue.7539, pp.409-412, 2015. ,
Nusinersen versus sham control in later-onset spinal muscular atrophy, New England Journal of Medicine, vol.378, issue.7, pp.625-635, 2018. ,
A microRNA switch regulates the rise in hypothalamic GnRH production before puberty, Nature Neuroscience, vol.19, issue.6, pp.835-844, 2016. ,
Definition and identification of small RNA sponges: Focus on miRNA sequestration, Methods, vol.117, pp.35-47, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01502131
Ribonuclease H (hybrid) in Escherichia coli. Identification and characterization, The Journal of Biological Chemistry, vol.248, issue.7, pp.2621-2624, 1973. ,
An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus, Genomics, vol.2, issue.1, pp.90-95, 1988. ,
Evaluation of 2 0 -modified oligonucleotides containing 2 0 -deoxy gaps as antisense inhibitors of gene expression, The Journal of Biological Chemistry, vol.268, issue.19, pp.14514-14522, 1993. ,
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy, Proceedings of the National Academy of Sciences, vol.106, issue.33, pp.13915-13920, 2009. ,
Dystrophin and mutations: One gene, several proteins, multiple phenotypes. The Lancet Neurology, vol.2, pp.731-740, 2003. ,
Introduction of a chimeric Chalcone synthase gene into Petunia results in reversible cosuppression of homologous genes in trans, The Plant Cell, vol.2, issue.4, pp.279-289, 1990. ,
The role of peroxiredoxins in cancer, Molecular and Clinical Oncology, vol.6, issue.2, pp.139-153, 2017. ,
Sequence-selective recognition of DNA by strand displacement with a thyminesubstituted polyamide, Science, vol.254, issue.5037, pp.1497-1500, 1991. ,
Formation and repair of Interstrand cross-links in DNA, Chemical Reviews, vol.106, issue.2, pp.277-301, 2006. ,
Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity, Clinical Cancer Research, vol.23, issue.7, pp.1771-1784, 2017. ,
Expanded CTG repeats within the DMPK 3 0 UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy, Proceedings of the National Academy of Sciences, vol.105, issue.7, pp.2646-2651, 2008. ,
Targeted therapy in severe asthma today: Focus on immunoglobulin E. Drug Design, Development and Therapy, vol.11, 1979. ,
, Fomivirsen. Drugs, vol.57, issue.3, pp.375-380, 1999.
Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration, Biochemical Pharmacology, vol.54, issue.6, pp.657-668, 1997. ,
Antisense molecules: A new class of drugs, Journal of Allergy and Clinical Immunology, vol.137, issue.5, pp.1334-1346, 2016. ,
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice, Nucleic Acids Research, vol.42, issue.13, pp.8796-8807, 2014. ,
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle, Nucleic Acids Research, vol.47, issue.12, pp.6029-6044, 2019. ,
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial, The Lancet, vol.375, issue.9719, pp.998-1006, 2010. ,
Mechanisms of activation of the paternally expressed genes by the Prader-Willi imprinting center in the Prader-Willi/Angelman syndromes domains, Proceedings of the National Academy of Sciences of the United States of America, vol.109, pp.7403-7408, 2012. ,
Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol, New England Journal of Medicine, vol.376, issue.15, pp.1430-1440, 2017. ,
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: Results of a phase 1b trial, Journal for Immunotherapy of Cancer, vol.6, issue.1, p.119, 2018. ,
Antisense properties of tricyclo-DNA, Nucleic Acids Research, vol.30, issue.13, pp.2751-2757, 2002. ,
Mipomersen, Cardiology in Review, vol.20, issue.2, pp.1-95, 2012. ,
Antisense oligonucleotides: The next frontier for treatment of neurological disorders, Nature Reviews Neurology, vol.14, issue.1, pp.9-21, 2017. ,
Fomivirsen approved for CMV retinitis, Journal of the International Association of Physicians in AIDS Care, vol.4, issue.10, pp.14-16, 1998. ,
Pivotal trial of Enfortumab Vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy, Journal of Clinical Oncology, vol.37, pp.2592-2600, 2019. ,
The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine, The Oncologist, vol.14, issue.4, pp.320-368, 2009. ,
A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by Quinacrine fluorescence and Giemsa staining, Nature, issue.5405, pp.290-293, 1973. ,
Molecular subtypes of small cell lung cancer: A synthesis of human and mouse model data, Nature Reviews Cancer, vol.19, issue.5, pp.289-297, 2019. ,
MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases, Nature Reviews Drug Discovery, vol.16, issue.3, pp.203-222, 2017. ,
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.35, issue.3, pp.689-699, 2015. ,
Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis, Journal of Cystic Fibrosis, vol.18, issue.4, pp.536-542, 2019. ,
Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H, Bioorganic & Medicinal Chemistry, vol.6, issue.10, p.131, 1998. ,
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index, Nature Biotechnology, vol.37, issue.6, pp.640-650, 2019. ,
Protein kinase a regulates cholinergic gene expression in PC12 cells: REST4 silences the silencing activity of neuron-restrictive silencer factor/REST, Molecular and Cellular Biology, vol.19, issue.10, pp.6788-6795, 1999. ,
A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer, Scientific Reports, vol.9, issue.1, 2019. ,
Duchenne muscular dystrophy: Current cell therapies, Therapeutic Advances in Neurological Disorders, vol.8, pp.166-177, 2015. ,
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy, Nature Reviews Cancer, vol.19, issue.9, pp.495-509, 2019. ,
Crystal structure of argonaute and its implications for RISC slicer activity, Science, issue.5689, pp.1434-1437, 2004. ,
Tricyclo-DNA: A phosphodiester-backbone based DNA analog exhibiting strong complementary basepairing properties, Journal of American Chemical Society, vol.119, pp.11548-11549, 1997. ,
Physicochemical properties of phosphorothioate oligodeoxynucleotides, Nucleic Acids Research, vol.16, issue.8, pp.3209-3221, 1988. ,
Inhibition of microRNA function by antimiR oligonucleotides, Silence, vol.3, issue.1, 2012. ,
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proceedings of the National Academy of Sciences of the United States of America, vol.75, pp.285-288, 1978. ,
Clinical potential of oligonucleotide therapeutics against pancreatic cancer, International Journal of Molecular Sciences, vol.20, p.3331, 2019. ,
Asialoglycoprotein receptor 1 mediates productive uptake of N-Acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes, Nucleic Acids Research, vol.45, issue.21, pp.12388-12400, 2017. ,
Gene therapy in patients with transfusion-dependent ?-thalassemia, New England Journal of Medicine, vol.378, issue.16, pp.1479-1493, 2018. ,
, , 2020.
, Lipoprotein(a) reduction in persons with cardiovascular disease, The New England Journal of Medicine, vol.382, issue.3, pp.244-255
Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma, Alimentary Pharmacology and Therapeutics, vol.43, issue.1, pp.102-113, 2016. ,
Local dystrophin restoration with antisense oligonucleotide PRO051, New England Journal of Medicine, vol.357, issue.26, pp.2677-2686, 2007. ,
Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells, Human Molecular Genetics, vol.10, issue.15, pp.1547-1554, 2001. ,
Locked nucleic acid as a novel class of therapeutic agents, RNA Biology, vol.6, issue.3, pp.321-323, 2009. ,
, A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS, American Journal of Ophthalmology, vol.133, issue.4, pp.1327-1329, 2002.
Noncoding RNAs in cancer therapy resistance and targeted drug development, Journal of Hematology & Oncology, vol.12, issue.1, 2019. ,
A genetic screen for candidate tumor suppressors identifies REST, Cell, vol.121, issue.6, pp.837-848, 2005. ,
Targeting nuclear RNA for in vivo correction of myotonic dystrophy, Nature, vol.488, issue.7409, pp.111-115, 2012. ,
Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway, Molecular Cancer, vol.18, issue.1, p.20, 2019. ,
DNA-based digital tension probes reveal integrin forces during early cell adhesion, Nature Communications, vol.5, issue.1, 2014. ,
The powerful world of antisense oligonucleotides: From bench to bedside, WIREs RNA, 1594. ,
URL : https://hal.archives-ouvertes.fr/hal-02565099